BMJ Open (Jun 2023)

Analysing COVID-19 treatment outcomes in dedicated wards at a large university hospital in northern Poland: a result-based observational study

  • Radosław Owczuk,
  • Krzysztof Kuziemski,
  • Damian Krystian Palus,
  • Martyna Ewa Gołębiewska,
  • Olga Piątek,
  • Krzysztof Grudziński,
  • Alan Majeranowski,
  • Tomasz Stefaniak

DOI
https://doi.org/10.1136/bmjopen-2022-066734
Journal volume & issue
Vol. 13, no. 6

Abstract

Read online

Objectives Presenting outcomes of patients hospitalised for COVID-19 should be put in context and comparison with other facilities. However, varied methodology applied in published studies can impede or even hinder a reliable comparison. The aim of this study is to share our experience in pandemic management and highlight previously under-reported factors affecting mortality. We present outcomes of COVID-19 treatment in our facility that will allow for an intercentre comparison. We use simple statistical parameters—case fatality ratio (CFR) and length of stay (LOS).Setting Large clinical hospital in northern Poland serving over 120 000 patients annually.Participants Data were collected from patients hospitalised in COVID-19 general and intensive care unit (ICU) isolation wards from November 2020 to June 2021. The sample consisted of 640 patients—250 (39.1 %) were women and 390 (60.9 %) were men, with a median age of 69 (IQR 59–78) years.Results Values of LOS and CFR were calculated and analysed. Overall CFR for the analysed period was 24.8%, varying from 15.9 % during second quarter 2021 to 34.1% during fourth quarter 2020. The CFR was 23.2% in the general ward and 70.7% in the ICU. All ICU patients required intubation and mechanical ventilation, and 44 (75.9 %) of them developed acute respiratory distress syndrome. The average LOS was 12.6 (±7.5) days.Conclusions We highlighted the importance of some of the under-reported factors affecting CFR, LOS and thus, mortality. For further multicentre analysis, we recommend broad analysis of factors affecting mortality in COVID-19 using simple and transparent statistical and clinical parameters.